Compare Stocks → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:ADDXFNASDAQ:BLCMNASDAQ:CNSPNASDAQ:KTOV Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADDXFAddex Therapeutics$0.99$0.99$0.99▼$0.99N/A0.25N/AN/ABLCMBellicum Pharmaceuticals$0.07-6.6%$0.08$0.06▼$1.31$727K1.3922,874 shs6,000 shsCNSPCNS Pharmaceuticals$0.20$0.31$0.19▼$2.98$2.15M2.67195,245 shs83,266 shsKTOVPurple Biotech$0.45$4.16$2.20▼$14.40$7.13M2.371.18 million shs102,394 shs7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADDXFAddex Therapeutics0.00%0.00%0.00%0.00%0.00%BLCMBellicum Pharmaceuticals0.00%0.00%0.00%-25.20%-77.84%CNSPCNS Pharmaceuticals-1.44%-16.83%-47.33%-64.57%-89.47%KTOVPurple Biotech0.00%-25.93%-32.20%-24.44%-76.67%This Apple-like Innovator is Revolutionizing Healthcare (Ad)AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industryMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADDXFAddex TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABLCMBellicum PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACNSPCNS PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AKTOVPurple BiotechN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADDXFAddex TherapeuticsN/AN/AN/AN/ABLCMBellicum PharmaceuticalsN/AN/AN/AN/ACNSPCNS PharmaceuticalsN/AN/AN/AN/AKTOVPurple BiotechN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADDXFAddex TherapeuticsN/AN/AN/AN/AN/AN/ABLCMBellicum Pharmaceuticals$1.50M0.48N/AN/A$0.23 per share0.33CNSPCNS PharmaceuticalsN/AN/AN/AN/A($0.71) per shareN/AKTOVPurple Biotech$1M7.13N/AN/A$5.56 per share0.08Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADDXFAddex TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/ABLCMBellicum Pharmaceuticals-$24.97MN/A0.00∞N/AN/AN/A-157.93%N/ACNSPCNS Pharmaceuticals-$18.85M-$5.66N/A∞N/AN/A-603.40%-421.35%5/20/2024 (Estimated)KTOVPurple Biotech-$5.85M-$3.00N/AN/AN/AN/AN/AN/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADDXFAddex TherapeuticsN/AN/AN/AN/AN/ABLCMBellicum PharmaceuticalsN/AN/AN/AN/AN/ACNSPCNS PharmaceuticalsN/AN/AN/AN/AN/AKTOVPurple BiotechN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADDXFAddex TherapeuticsN/AN/AN/ABLCMBellicum PharmaceuticalsN/A3.043.04CNSPCNS PharmaceuticalsN/A0.260.26KTOVPurple BiotechN/A2.22N/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipADDXFAddex TherapeuticsN/ABLCMBellicum Pharmaceuticals4.93%CNSPCNS Pharmaceuticals14.02%KTOVPurple Biotech30.72%Insider OwnershipCompanyInsider OwnershipADDXFAddex TherapeuticsN/ABLCMBellicum Pharmaceuticals10.30%CNSPCNS Pharmaceuticals3.88%KTOVPurple Biotech2.98%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADDXFAddex Therapeutics26N/AN/ANot OptionableBLCMBellicum Pharmaceuticals139.72 million8.72 millionNot OptionableCNSPCNS Pharmaceuticals310.64 million10.22 millionNot OptionableKTOVPurple Biotech915.73 millionN/ANot OptionableADDXF, BLCM, KTOV, and CNSP HeadlinesSourceHeadlinePromising Pipeline Prospects for Purple Biotech: Buy Rating Affirmed Amidst Anticipated Clinical Advancementsmarkets.businessinsider.com - March 6 at 3:56 PMPurple Biotech: Q3 Earnings Insightsbenzinga.com - November 21 at 9:06 AMPurple Biotech GAAP EPS of -$0.23msn.com - November 21 at 9:06 AMPurple Biotech files to sell 4.65M ADS for holdersmsn.com - October 30 at 6:19 PMAlukovinyl Provides Customised And Innovative Purple Car Wrap Films For Car Owners Worldwidebenzinga.com - August 25 at 6:47 AMPurple Biotech Stock (NASDAQ:PPBT), Earnings Estimates, EPS, and Revenuebenzinga.com - August 24 at 8:36 PMPurple Biotech Reports Second Quarter 2023 Financial Resultsbenzinga.com - August 22 at 1:56 PMPPBT Purple Biotech Ltd.seekingalpha.com - July 19 at 1:35 PMPurple Carrot Discount Codeslatimes.com - July 9 at 4:56 PMPurple Promo Codes 2023reuters.com - June 29 at 12:46 PMPurple Biotech (PPBT) Receives a Buy from H.C. Wainwrightmarkets.businessinsider.com - May 17 at 7:09 AMPurple Biotech CEO Gil Efron takes medical leave, Isaac Israel named acting CEOseekingalpha.com - March 24 at 10:06 AMPurple Biotech sees positive results from cancer studylabiotech.eu - March 19 at 7:49 PMRapidly Growing Purple Brands Announces New Director of Winemakingfinance.yahoo.com - September 9 at 4:41 PM‘Purple Hearts’ Star Sofia Carson and Director Elizabeth Allen Rosenbaum Defend Netflix Film After Backlash: ‘Our Intentions Are Very Pure’finance.yahoo.com - August 12 at 7:23 PMDebut Biotech and DIC team up to make Holy Grail in natural food colors: a stable vibrant redfoodnavigator-usa.com - July 28 at 12:10 PMPurple Biotech Names Efron CEO as Israel Steps Down >PPBTmarketwatch.com - July 14 at 10:01 AMBiotech company says woman received 3D printed ear made from her own cellsyahoo.com - June 2 at 3:47 PMPurple Biotech Reports First Quarter 2022 Financial Resultsfinance.yahoo.com - May 12 at 12:16 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAddex TherapeuticsOTCMKTS:ADDXFAddex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.Bellicum PharmaceuticalsNASDAQ:BLCMBellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.CNS PharmaceuticalsNASDAQ:CNSPCNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.Purple BiotechNASDAQ:KTOVPurple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. is headquartered in Tel Aviv, Israel. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.